Menu Search
Equities

Solasia Pharma KK

  • Add to watchlist
  • Add to portfolio
  • Add an alert
9SO:STU

Solasia Pharma KK

Actions
  • Price (EUR)0.143
  • Today's Change0.006 / 4.38%
  • Shares traded0.00
  • 1 Year change-35.59%
  • Beta0.3529
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Solasia Pharma KK is a Japan-based company with a product development pipeline of pharmaceuticals and medical devices, and is engaged in the development and sale of pharmaceuticals. Its main business area is the development and sale of pharmaceuticals for the treatment of malignant tumors. It also develops and sells pharmaceuticals and medical devices that are expected to reduce adverse events caused by the administration of malignant tumor treatment drugs and radiation therapy, and improve the treatment of malignant tumors and the quality of life (QOL) of patients. It is engaged in in-licensing of rights for pharmaceutical or medical device candidate substances, development of pharmaceutical candidates, and monetization of pharmaceutical candidates. Its development pipeline includes the transdermal granisetron preparation Sancuso, the organic arsenic preparation darinaparsin, the oral wound dressing protective material episil, and the intracellular superoxide remover PledOx.

  • Revenue in JPY (TTM)326.00m
  • Net income in JPY-1.80bn
  • Incorporated2007
  • Employees23.00
  • Location
    Solasia Pharma KK3F, Shiodome Bldg., 1-2-20, KaiganMINATO-KU 105-0011JapanJPN
  • Phone+81 358438045
  • Fax+81 367212020
  • Websitehttps://solasia.co.jp/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.